secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001193125-23-283354
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte exercises option for manufacturing rights; pays $50M upfront
--------------------------------------------------------------------

- Exercised option on Nov 21, 2023; paid $50M cash; owes $25M within 6 months.
- Manufacturing Rights Agreement grants exclusive, perpetual, royalty-free license to manufacture Extract for vaccines.
- Up to $60M in additional milestone payments upon regulatory milestones.
- Amendments to License and Supply Agreements to ensure consistency with new agreement.
- Option allows Vaxcyte to directly source Extract from CMOs and independently develop improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523283354/0001193125-23-283354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523283354/d592234d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-283354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer